Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside [Seeking Alpha]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Seeking Alpha
COGT's bezuclastinib showed a 50% reduction in disease progression risk and superior objective response rates versus standard of care. Strong PEAK data de-risks upcoming readouts and supports blockbuster revenue projections, with analysts targeting $1.5bn peak sales and a $3-4bn valuation. Despite single-asset risk and cash burn, the strength of clinical data and market potential make COGT stock a compelling long-term buy-and-hold opportunity. The opportunity to secure approvals in advanced and non-advanced systemic mastocytosis by 2027 only enhances the value proposition. hernan4429/iStock via Getty Images Investment Overview Cogent Biosciences, Inc. ( COGT ) stock went stratospheric yesterday, gaining ~120% to reach a value of $42.5, after the Waltham, Massachusetts based biotech reported positive results from its Phase 3 PEAK study More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare in
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences (NASDAQ:COGT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Announces Participation in the Jefferies Global Healthcare ConferenceGlobeNewswire
- Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
COGT
Sec Filings
- 11/18/25 - Form 8-K
- 11/17/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- COGT's page on the SEC website